 |
Technical Support
(877) SEPAX-US, press 3  TechSupport@sepax-tech.com |
  |
| By Separation Mode | By Brand | By Sample Based Application | |
|
Size Exclusion Ion Exchange Hydrophobic Interaction Ion Exclusion Sub-2 UHPLC Purification Reversed Phase Mixed-mode Phase HILIC View All |
SEC-MALS Unix / Unix-C Zenix / Zenix-C SRT / SRT-C SRT-10 / SRT-10C Proteomix HIC / IEX Antibodix Carbomix Proteomix RP View All |
ADC Antibody Biosimilar Carbohydrate Cell Lysate DNA/RNA Fusion Protein Glycan Glycoprotein Heparin |
Insulin Membrane Protein Organic Acid PEG/PEGylated Protein Peptide Polymer Protein Vaccine/VLP Others |
How May We Help You?
How May We Help You?
How May We Help You?
Your question has been submitted.
We will respond back to you shortly.
We will respond back to you shortly.
How May We Help You?
Please fill out all required fields.
Samples
Sample: AntibodyAntibody Recommended products
Size Exclusion:
Unix
Zenix
Zenix-C
SRT
SRT-C
Preparative SEC
Ion Exchange: Proteomix Antibodix Reversed phase: Proteomix RP Bio-C4
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Application Note
Featured Application Notes
All Application Notes
| App ID | Title |
| LR2024051507 | Literature Reference: Structure-function Relationship Study for Sulfated Protein Therapeutics Using Hydrophobic Interaction Chromatography and Mass Spectrometry | Hydrophobic InteractionProteomix HIC HIC, Mass Spec, BsMabHPLC1
| LR2024071523 | Literature Reference: In-Depth Characterization for Methionine Oxidization in Complementary Domain Region by Hydrophobic Interaction Chromatography | Hydrophobic InteractionProteomix HICMonoclonal AntibodiesHPLC1
| LR2024021491 | Literature Reference: Online Multimethod Platform for Comprehensive Characterization of Monoclonal Antibodies in Cell Culture Fluid From a Single Sample Injection - Intact Protein Workflow | Ion ExchangeProteomix SCX-NP3Charge Variant, SEC and Mass, Characterization of MabsUV1
| LR202202139 | Literature Reference: A novel twin-column continuous chromatography approach for separation and enrichment of monoclonal antibody charge variants | IEXProteomix@AntibodixPurificationHPLC@FPLC1
| UNIXP1002 | Unix 1.8 µm UHPLC SEC for Fast Ultra High Resolution Biomolecule Separation | Size ExclusionUnixResolution@Aggregates@Fast Assay@Column Stability@Lot to Lot@Particle Size Impact@LoadingHPLC@UHPLC1
| ZM1019 | Analytical Characterization of Antibody Drug Conjugates | Size Exclusion@Ion Exchange@Reversed PhaseZenix-C@Proteomix@Proteomix RPMethod Optimization@Volatile Buffer@Packing Chemistry@Fast Assay@MAb Fragment@Charge Variants@Aggregates@Resolution@Competition Comparison@Orthogonal MethodHPLC@LCMS1
| PM1008 | MAb on Proteomix SCX - pH Gradient | Ion ExchangeProteomixLot to Lot@Method Optimization@Loading@Charge Variants@Fast Assay@Competition ComparisonHPLC1
| PM1001 | MAb on Proteomix SCX vs. Antibodix WCX NP5 | Ion ExchangeProteomix@AntibodixMethod Optimization@Loading@Resolution@Charge Variants@Packing Chemistry@Competition Comparison HPLC1
| ZZ1003 | Fast Separation of MAb and its Aggregates in Less Than 3 Mins | Size ExclusionZenixFast Assay@Lot to LotHPLC1
| LR2024021489 | Literature Reference: Absolute Quantitation of Binding Antibodies from Clinical Samples | Size ExclusionUnix-CSize Exclusion, VLP/Virus/Vaccine, AntibodyHPLC1
| KM1004 | Monoclonal Antibody Purification by Sepax MabPurix A65 Protein A Affinity | AffinityMabPurix Protein AN/AHPLC1
| KM1003 | Technical Specification - MabPurix Protein A Affinity vs. Other Brands | AffinityMabPurix Protein AN/AHPLC1
| KM1002 | Purification of Tribody by Sepax MabPurix A45 Protein A Affinity | AffinityMabPurix Protein AN/AHPLC1
| KM1001 | Purification of Bispecific Antibody by Sepax MabPurix P45 Protein A Affinity | AffinityMabPurix Protein AN/AHPLC1
| LR2022051235 | Literature Reference: Development of a robust and semi-automated two-step antibody purification process | Size ExclusionSRT-10CPurification, Method OptimizationAKTA Pure1
| LR202202580 | Literature Reference: EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies | Size ExclusionZenixBispecific Antibody Separation@Aggregates@Fast Assay@MAb FragmentUHPLC1
| LR202202197 | Literature Reference: Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product | Ion ExchangeProteomixOrthogonal Method@Charge Variants@Antibody Production@MAb FragmentHPLC2
| FM1001 | Sepax's ProAqa Excel Protein A Affinity Column for Fast Antibody Titer Determination | AffinityProAqa ExcelFast AssayHPLC@UHPLC@FPLC2
| Overview | Sepax Overview | Ion ExchangeZenixSeparation of ProteinsHPLC2
| BM1002 | Bispecific Antibody Separation on Sepax BioMix Mixed Mode SEC Column | Size ExclusionBioMixBispecific Antibody SeparationHPLC2
| BM1001 | Literature Reference: Characterization of bispecific antibody production in cell cultures by unique mixed mode size exclusion chromatography | Size ExclusionBioMixAntibody ProductionHPLC2
| PM1024 | Charge Variants Analysis of CetuximAb with pH Gradient : CEX-HPLC Vendor Comparison | Ion ExchangeProteomixMethod Optimization@Charge VariantsHPLC2
| ZM1029 | Custom Affinity Using HSA as the Immobilized Ligand to Assess mAb Immunogen Cross-Reactivity | AffinityZenixResolution@Orthogonal MethodHPLC@FPLC2
| ZM1028 | Custom Affinity Using HSA as the Immobilized Ligand to Assess mAb Immunogen Cross-Reactivity | AffinityZenixResolution@Orthogonal MethodHPLC@FPLC2
| PM1023 | NIST mAb CEX Separation - Competition Comparison | Ion ExchangeProteomix@Proteomix SCXMethod Optimization@Resolution@Orthogonal Method@Charge VariantsHPLC2
| ZM1027 | Analytical Characterization of NIST MAb by Size Exclusion Chromatography | Size ExclusionZenixMethod Optimization@Resolution@Orthogonal MethodHPLC2
| PM1022 | Analytical Characterization of NIST MAb by Sepax SEC, HIC, RP and CEX | Ion Exchange@Reversed Phase@Hydrophobic Interaction@Size ExclusionProteomix@Proteomix SCX@Proteomix WCX@Antibodix@Proteomix RP@Proteomix HIC@ZenixMethod Optimization@Resolution@Orthogonal Method@Charge VariantsHPLC2
| PM1021 | Analytical Characterization of NIST MAb by Reversed Phase Chromatography (RP) | Reversed PhaseProteomix RPResolution@Orthogonal MethodHPLC2
| HICM1010 | Analytical Characterization of NIST MAb by Hydrophobic Interaction Chromatography (HIC) | Hydrophobic InteractionProteomix HICMethod Optimization@Resolution@Orthogonal MethodHPLC2
| PM1020 | NIST MAb Charge Variants Analysis by Cation Exchange Chromatography | Ion ExchangeProteomix@Proteomix SCX@Proteomix WCX@AntibodixMethod Optimization@Charge VariantsHPLC2
| WM1003 | Fast Monoclonal Antibody Titer Determination Followed by SEC Aggregation Analysis | Size ExclusionProtein A-Sil@Unix-CResolution@Fast Assay@Particle Size Impact@AggregatesHPLC@UHPLC2
| EM1007 | Analytical Characterization of Monoclonal Antibody IgG2 | Size Exclusion@Ion Exchange@Hydrophobic Interaction@Reversed PhaseProteomix@Zenix-C@Unix-C@Proteomix SCX@Proteomix HIC@Proteomix RPResolution@Particle Size Impact@SEC-MALS@ Hydrophobicity@Charge Variants@Aggregates@Orthogonal MethodHPLC2
| WM1001 | MAb Separation on Unix-C SEC-300 UHPLC Column | Size ExclusionUnix-CResolution@Aggregates@Column Stability@Lot to Lot@Particle Size Impact@LoadingUHPLC3
| PM1019 | PM1019 - MAb IgG1 and IgG2 Charge Variants Separation by Narrow-bore (2.1 mm I.D.) SCX Column | Ion ExchangeProteomixCharge Variants@Method Optimization@Loading@Resolution@SensitivityHPLC3
| HICM1009 | HICM1009- Mab Analysis on Proteomix® HICNP5 phases (4603) | Hydrophobic InteractionProteomix@Proteomix HICResolution@Hydrophobicity@Packing ChemistryHPLC3
| EM1006 | EM1006 - Bispecific mAb SEC analysis | Size ExclusionZenixResolution@Aggregates@Pore Size SelectionHPLC3
| EM1005 | Rituximab analysis using Zenix-C Light Scattering SEC -MALS 300 | Size ExclusionZenix-CResolution@Purification@Optimization@SEC-MALSHPLC3
| SM1004 | mAb purification on SRT SEC-300 21.1x300 mm | Size ExclusionSRTResolution@Purification@Aggregates@Fast AssayFPLC3
| HICM1008 | Intact and Oxidized MAb Analysis on Proteomix HIC Butyl 1.7 µm | Hydrophobic InteractionProteomix@Proteomix HICCompetition Comparison@Resolution@Method Optimization@Particle Size ImpactHPLC@UHPLC3
| PM1018 | Column Temperature Effect on mAb Separation on Reversed Phase Chromatography | Reversed PhaseProteomix@Proteomix RPVolatile Buffer@Method Optimization@Resolution@LoadingHPLC@LCMS3
| PM1017 | Monoclonal antibody charge variants separation on Proteomix SCX NP3, UHPLC | Ion ExchangeProteomixFast Assay@Resolution@Method Optimization@Charge VariantsUHPLC3
| VM1001 | MAb Purification and Aggregates Removal on Generik MC30-HIC Butyl | Ion ExchangeGenerik MC-HICResolution@Purification@AggregatesHPLC@FPLC3
| ZM1026 | Reduced MAb Separation on Zenix SEC-300 2.1x300 with LC/MS Volatile Buffer | Size ExclusionZenixLoading@Resolution@Volatile BufferHPLC@LCMS3
| SM1003 | Sepax SEC Analytical Column Loading Capacity | Size Exclusion@Size ExclusionSRT@ZenixLoadingHPLC3
| HICM1004 | MAb hydrophobicity screening on Proteomix HIC Butyl-NP5 | Hydrophobic InteractionProteomix@Proteomix HICHydrophobicityHPLC3
| HICM1005 | Erbitux and Rituximab Monoclonal Antibody Separation on Proteomix HIC Butyl NP5 | Hydrophobic InteractionProteomix@Proteomix HICResolution@HydrophobicityHPLC3
| HICM1003 | MAb Loading from Analytical to Prep HIC | Hydrophobic Interaction@Hydrophobic InteractionProteomix@Proteomix HICLoadingHPLC3
| ZM1025 | IgE and IgG Separation on Zenix SEC-300 | Size ExclusionZenixResolution@AggregatesHPLC3
| HICM1002 | MAb Loading on Proteomix HIC Butyl-NP10 | Hydrophobic InteractionProteomix@Proteomix HICLoadingHPLC4
| ZM1024 | Intact MAb, ADC and their Fragment Analysis with SEC-MS | Size Exclusion@Size Exclusion@Size Exclusion@Size ExclusionZenix@Zenix-CMAb Fragment@Resolution@Volatile Buffer@Method Optimization HPLC@LCMS4
| ZM1023 | ADC vs. Free Drug Analysis | Size Exclusion@Size Exclusion@Size ExclusionZenix@Zenix-CResolution@Volatile Buffer@Pore Size Selection@Fast Assay@Method Optimization@Loading HPLC@LCMS4
| PM1016 | Intact MAb, ADC and their Fragments Analysis on RP LC/MS | Hydrophobic Interaction@Reversed Phase@Reversed PhaseProteomix HIC@Proteomix RPMAb Fragment@Resolution@Volatile Buffer@Method OptimizationHPLC@LCMS4
| ZM1022 | MAb/ADC Fragment Separation after IDeS Digestion | Size Exclusion@Size Exclusion@Hydrophobic Interaction@Reversed PhaseZenix@Zenix-C@Proteomix HIC@Proteomix RPMAb Fragment@Resolution@Volatile BufferHPLC/LCMS4
| ZM1021 | Fast MAb Analysis on Zenix SEC - Flow rate | Size ExclusionZenixFast Assay@Aggregates@Method Optimization@ResolutionHPLC4
| PM1015 | MAb Fragments on Proteomix RP | Reversed PhaseProteomix RPPore Size Selection@Method Optimization@MAb Fragment@Volatile BufferHPLC/LCMS4
| SM1015 | MAb Purification on SRT-10 300 | Size ExclusionSRT-10Resolution@Loading@Competition Comparison@Method Optimization@AggregatesFPLC4
| PM1013 | Intact and Reduced MAb/ADC and MAb Fragment Separation on RP | Reversed PhaseProteomix@Proteomix RPMethod Optimization@Volatile Buffer@Packing Chemistry@Fast Assay@MAb Fragment@Orthogonal MethodHPLC@LCMS@NanoLC4
| PM1010 | MAb Carboxypeptidase Digested on Proteomix SCX | Ion ExchangeProteomixMethod Optimization@Charge Variants@Sample Stability TestHPLC4
| EM1001 | SEC Packing Chemistry Impact on MAb Separation | Size ExclusionZenix@Zenix-CPacking Chemistry@AggregatesHPLC4
| ZM1020 | MAb Half Body TCEP Disulfide reduction | Size ExclusionZenixCompetition Comparison@MAb FragmentHPLC4
| SM1016 | IgM from Mouse Ascites on SRT SEC-500 | Size ExclusionSRTResolutionHPLC4
| PM1012 | MAb Innovator vs. its Biosimilar on Protoemix SCX | Ion ExchangeProteomixFast Assay@Charge Variants@Orthogonal MethodHPLC@UHPLC4
| ZM1018 | MAb and its ADCs Separation on SEC | Size ExclusionZenix@Zenix-CResolution@Packing Chemistry@Aggregates@Method OptimizationHPLC4
| ZM1017 | High Loading of MAb Fragments on Zenix 300 | Size ExclusionZenixMAb Fragment@LoadingHPLC4
| AM1013 | MAb Innovator vs. its Biosimilar on Zenix SEC and Antibodix WCX | Ion Exchange@Size ExclusionAntibodix@ZenixOrthogonal Method@Aggregates@Charge VariantsHPLC5
| PM1007 | MAb on Proteomix SCX - Flow rate | Ion ExchangeProteomixMethod Optimization@Charge VariantsHPLC5
| PM1006 | MAb on Proteomix vs. Competitor SCX - Salt Gradient | Ion ExchangeProteomixCompetition Comparison@Charge VariantsHPLC5
| PM1005 | MAb on Proteomix vs. Competitor SCX - pH and Salt Gradient | Ion ExchangeProteomixCompetition Comparison@Charge VariantsHPLC5
| PM1004 | Fast MAb Analysis on Proteomix SCX - Flow rate | Ion ExchangeProteomixFast Assay@Method Optimization@Charge VariantsHPLC5
| PM1003 | MAb fragment on Proteomix WCX NP1.7 | Ion ExchangeProteomixMAb Fragment@Fast Assay@Charge VariantsHPLC@UHPLC5
| PM1002 | MAb on Proteomix SCX NP1.7 vs. NP5 | Ion ExchangeProteomixFast Assay@Particle Size Impact@Charge VariantsHPLC@UHPLC5
| AM1012 | MAb on Antibodix WCX NP1.7 | Ion ExchangeAntibodixMethod Optimization@Fast Assay@Charge VariantsHPLC@UHPLC5
| AM1011 | MAb on Antibodix WCX - Particle Size and Loading | Ion ExchangeAntibodixLoading@Particle Size Impact@Fast Assay@Charge VariantsHPLC@UHPLC5
| ZM1011 | Fresh MAb Analysis on Zenix 300 | Size ExclusionZenixAggregates@Sample Stability TestHPLC5
| AM1010 | MAb on Antibodix WCX NP5 | Ion ExchangeAntibodixSample Stability Test@Charge VariantsHPLC5
| ZM1008 | MAb Fragments Separation and Characterization by SEC and SEC/MS | Size ExclusionZenixMAb Fragment@Volatile Buffer@Method OptimizationHPLC@LCMS5
| ZM1006 | MAb Heavy chain and Light Chain Separation by Zenix SEC | Size ExclusionZenixMAb Fragment@Volatile BufferHPLC@LCMS5
| ZM1005 | MAb Fragments Analysis on Zenix SEC-150 | Size ExclusionZenixMAb FragmentHPLC5
| ZM1004 | BevacizuMAb and Erbitux Antibodies by Zenix SEC-300 | Size ExclusionZenixAggregates@ResolutionHPLC5
| ZM1003 | Fast MAb analysis by Zenix SEC | Size ExclusionZenixFast AssayHPLC5
| ZM1002 | MAb High Resolution by Zenix SEC | Size ExclusionZenixAggregates@ResolutionHPLC6
| ZM1001 | Reproducibility for MAb Analysis on Zenix SEC | Size ExclusionZenixLot to LotHPLC6
| SM1002 | MAb & IgG on SRT SEC | Size ExclusionSRTResolutionHPLC6
| SM1001 | MAb on SRT SEC - LMW & HMW regions | Size ExclusionSRTLoading@Resolution@AggregatesHPLC6
| RM1001 | MAb on SRT-C SEC | Size ExclusionSRT-CAggregates@ResolutionHPLC6
| PC1002 | Separation of Glycan and Isomers on Proteomix SAX | Ion ExchangeProteomixResolutionHPLC@LCMS6
| AM1009 | Two MAb Comparison on Antibodix WCX NP3 | Ion ExchangeAntibodixCharge Variants@Fast AssayHPLC6
| AM1008 | MAb on Antibodix WCX Method Optimization-pH Impact | Ion ExchangeAntibodixMethod Optimization@Charge VariantsHPLC6
| AM1007 | MAb on Antibodix WCX Method Optimization-Initial Salt Impact | Ion ExchangeAntibodixMethod Optimization@Charge VariantsHPLC6
| AM1006 | MAb on Antibodix WCX Method Optimization-Gradient | Ion ExchangeAntibodixMethod Optimization@Charge VariantsHPLC6
| AM1005 | MAb Charge Variants on Antibodix WCX NP5 | Ion ExchangeAntibodixCharge VariantsHPLC6
| AM1004 | Antibodix WCX NP3 vs. NP5 vs. NP10 | Ion ExchangeAntibodixParticle Size Impact@Charge VariantsHPLC6
| AM1003 | Antibodix WCX NP3 vs. NP1.7 | Ion ExchangeAntibodixParticle Size Impact@Fast Assay@Charge VariantsHPLC@UHPLC6
| AM1002 | MAb Charge Variants on Antibodix WCX NP10 | Ion ExchangeAntibodixCharge VariantsHPLC6
| AM1001 | MAb on Antibodix vs. Competitor WCX | Ion ExchangeAntibodixCompetition Comparison@Resolution@Charge VariantsHPLC6
| PM1025 | AdalimumAb Charge Variants Separation From Analytical to PrepCation Exchange Chromatography(Humira Innovator and Biosimilar) | Ion ExchangeProteomix@AntibodixCharge Variants@Competition Comparison@Loading, Purification@ResolutionHPLC@FPLC6
| HICM1006 | Intact and Oxidized Monoclonal Antibody Separation on Proteomix HIC | Hydrophobic InteractionProteomix@Proteomix HICCompetition Comparison@Resolution@Method Optimization HPLC@UHPLC7
| LR2022081354 | Design and Characterization of Immune-Stimulating Imidazo45-cquinoline Antibody Drug Conjugates | RPProteomix RPADC Free Drug Analysis on Sepax Analytical RP ColumnHPLC@UHPLC7